Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Crestline Management, LP (CIK 1536054) reported $53.5M across 3 reported positions in its SEC 13F filing for 2026-06-30. Largest positions: DNLI ($49.1M, 91.90%), SANA ($2.6M, 4.93%), EGHT ($1.7M, 3.17%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | DNLI | DENALI THERAPEUTICS INC | $49.1M | 91.90% | 1.9M | Trimmed |
| 2 | SANA | SANA BIOTECHNOLOGY INC | $2.6M | 4.93% | 755,736 | Hold |
| 3 | EGHT | 8X8 INC NEW | $1.7M | 3.17% | 990,850 | Hold |
Source: SEC Form 13F filings · as of 2026-06-30